A regular course of treatment with bedaquiline usually takes several months

Bedaquiline is a new anti-tuberculosis drug used to treat multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB). According to the recommendations of the World Health Organization (WHO) and clinical guidelines from many countries, the standard treatment course of bedaquiline is continuous administration for 6 months. The specific plan is: take 400mg daily for the first 2 weeks, and then 22Change to taking 200mg 3 times a week until 6 months old. This "strong lead, weak maintenance" therapy has been proven to achieve a good balance between efficacy and tolerability.

Although6months is the recommended standard course of treatment, in some special clinical situations, such as patients who tolerate the drug well, have complicated infections, or are combined with other diseases, doctors may extend or adjust the use time of bedaquiline according to the condition. On the contrary, for some patients who experience severe adverse reactions, the treatment course may be appropriately shortened. Therefore, treatment courses should be individually tailored by a specialist based on patient response and safety.

Bedaquiline cannot be used alone for the treatment of tuberculosis. It must be used in combination with other effective anti-tuberculosis drugs to form a complete multi-drug treatment plan. Drugs often combined with it include linezolid, clofazimine, moxifloxacin, etc. The entire anti-tuberculosis treatment course may last as long as 9 to 20 months or even longer, while bedaquiline is only responsible for the core therapeutic effect in the first 6 months. Combination therapy not only helps prevent the development of drug resistance, but also improves the bacterial clearance rate.

Although bedaquiline has good initial efficacy, treating multidrug-resistant tuberculosis is a long-term and complex process. If patients stop taking the drug or reduce the dose without authorization, it may lead to treatment failure and aggravation of drug resistance. Therefore, regular follow-up and monitoring of electrocardiogram (bedaquiline can prolong QT interval) and liver function indicators are necessary during the medication period to ensure safe and effective completion of the entire course of treatment. For patients, understanding the importance of treatment and overcoming the psychological barriers of long-term medication are important guarantees for successful treatment.

Reference materials:https://www.drugs.com/